Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update [Yahoo! Finance]
VistaGen Therapeutics, Inc. (VTGN)
Last vistagen therapeutics, inc. earnings: 2/13 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.vistagen.com
Company Research
Source: Yahoo! Finance
10 min read In This Article VTGN Fasedienol U.S. registration-directed PALISADE Phase 3 Program for acute treatment of social anxiety disorder progressing with ongoing PALISADE-3, PALISADE-4 and Repeat Dose trials Vistagen highlights clinical-stage pipeline with five novel pherine product candidates with positive efficacy signals and potential to transform standards of care for multiple high prevalence indications SOUTH SAN FRANCISCO, Calif., February 13, 2025 BUSINESS WIRE Vistagen (Nasdaq: VTGN), a clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today reported financial results for its fiscal year 2025 third quarter ended December 31, 2024, and provided a corporate update. "We had a very productive quarter, with both PALISADE-3 and PALISADE-4 advancing towards expected top-line results later this year," said Shawn Singh, President
Show less
Read more
Impact Snapshot
Event Time:
VTGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VTGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VTGN alerts
High impacting VistaGen Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
VTGN
News
- Vistagen Appoints Nick Tressler as Chief Financial OfficerBusiness Wire
- Vistagen Reports Findings on PH80’s Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual MeetingBusiness Wire
- Vistagen Therapeutics: Intranasal Pherines And A Make-Or-Break 2026 [Seeking Alpha]Seeking Alpha
- VistaGen Therapeutics (NASDAQ:VTGN) was given a new $12.00 price target on by analysts at Stifel Nicolaus.MarketBeat
- Vistagen Therapeutics Inc (VTGN) Q2 2026 Earnings Call Highlights: Progress in Palisade 3 Trial ... [Yahoo! Finance]Yahoo! Finance
VTGN
Earnings
- 11/13/25 - Miss
VTGN
Sec Filings
- 12/4/25 - Form 4
- 12/4/25 - Form 3
- 12/3/25 - Form 8-K
- VTGN's page on the SEC website